Northern California

Neuropsychology Forum

Back

The Role of Biomarkers in the Diagnosis and Treatment of Neurodegenerative Diseases

When
March 30, 2023
6:00 PM - 8:00 PM
Location
Online Webinar via Zoom

Registration

Allied Professionals – $55.00
Allied Professionals includes non-doctoral level health providers working in clinical psychology or related areas, such as MFTs, social workers, occupational therapists, speech therapists, physical therapists, etc.
Allied Professionals (Earlybird Rate) – $35.00
Allied Professionals includes non-doctoral level health providers working in clinical psychology or related areas, such as MFTs, social workers, occupational therapists, speech therapists, physical therapists, etc.
Board Member
This registration is strictly open to board Members only
Emeritus Members – $55.00
Emeritus Members (Earlybird Rate) – $35.00
Non-Member Professionals – $110.00
Non-Member Professionals (Earlybird Rate) – $95.00
Professional/Affiliate Members – $90.00
Professional/Affiliate Members (Earlybird Rate) – $70.00
Student Members – $10.00
Student Non-Members – $20.00

Registration is closed

The Role of Biomarkers in the Diagnosis and Treatment of Neurodegenerative Diseases,

with Armen Moughamian, MD, PhD

Date: Thursday, March 30th

Time: 6-8 pm PST

Live Webinar via Zoom

Armen Moughamian, MD, PhD, is a neurologist who cares for people with neurodegenerative brain illnesses including Alzheimer's disease and other dementias, as well as movement disorders, such as Huntington's disease and spinocerebellar ataxias. Board certified in neurology, Dr. Moughamian is medical director of the Ray Dolby Brain Health Center at Sutter's California Pacific Medical Center. There, he is also the vice-chair of neuroscience and division chief of neurology. Dr. Moughamian received his medical degree and PhD in neuroscience from the Perelman School of Medicine at the University of Pennsylvania. He completed a medical internship and neurology residency at the University of California, San Francisco, followed by a research fellowship and clinical work at UCSF's Memory and Aging Center. He is currently a principal investigator on several clinic trials for Alzheimer's and dementia, including TRAILBLAZER-ALZ 3, ENVISION, and New IDEAS. In addition, he a clinical assistant professor of neurology at the Geisel School of Medicine at Dartmouth.

Learning Objectives: Upon completion of this workshop, the participants will be able to:

Describe why biomarkers are used in the diagnosis of neurodegenerative diseases.
Identify at least 3 different biomarkers used in neurodegenerative disease.
Summarize the appropriate use criteria for CSF and PET Alzheimer's biomarkers.
Describe the clinical population studied, clinical effect and side effects of new anti-amyloid therapies in early Alzheimer's disease.

Early Bird rates through Thursday, March 23rd!

Email events@ncnf.org with any questions.

APA & QME CEUs: 2

Webinar will be live-interactive and meets criteria for live CE hours

NCNF is approved by the American Psychological Association to sponsor continuing education for psychologists. NCNF maintains responsibility for this program. NCNF is also approved for continuing education for Qualified Medical Examiners (QME).